BPH Treatment Market Future Prospects
The global benign prostatic hyperplasia treatment market size is USD 13,662.6 million in 2024, and it is projected to reach USD 19,067.9 million in 2030, with a growth rate of 5.7% during 2025–2030. The soaring prevalence of BPH, surging preference for minimally invasive surgeries, and increasing investments, funds, and grants for conducting research on new treatments are the prominent contributors to the progress.
Moreover, the burgeoning aging population, particularly the geriatric male segment, is a major driver of BPH incidence, which, in turn, fuels the demand for medications across the globe. In addition to this, the adoption of minimally invasive surgeries has been flourishing significantly due to their less post-operative pain, reduced hospital stays, less blood loss, and faster recovery. This expands the production of minimally surgically surgical instruments, thus leading to their easy availability for healthcare settings.
Technology has played a crucial part in most of the recent advancements in benign prostatic hyperplasia management, no more so than in the rise of procedures that do not necessitate general anesthesia or prolonged hospital stays. There is a novel mechanical implant available for the prostate that moves its invading lobes out of the way, to enhance urine flow. Furthermore, a device known as UroLift has shown to cause minimal disruption during ejaculation and, when compared to the traditional surgery, known as TURP, in a recent trial, had similar outcomes, including patient satisfaction with minimal complications.
In addition to this, prostatic artery embolization is a new technique that is performed by an interventional radiologist. Performed under a local anesthetic, it involves a groin artery puncture with the super-selective vascular embolization of the arteries to the prostate. This is postulated to cause a shrinkage of the prostate and an improvement in urinary function.